Advances in cancer research最新文献

Cerebrospinal fluid considerations in glioma. 脑胶质瘤中脑脊液的考虑。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-06 DOI: 10.1016/bs.acr.2025.05.002

Shelei Pan, Jennifer M Strahle

{"title":"Cerebrospinal fluid considerations in glioma.","authors":"Shelei Pan, Jennifer M Strahle","doi":"10.1016/bs.acr.2025.05.002","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.05.002","url":null,"abstract":"Cerebrospinal fluid (CSF) circulates in the ventricular system and subarachnoid space, and through its interaction with interstitial fluid, facilitates nutrient and waste exchange to support the functional needs of cells in the brain and spinal cord. In the setting of primary brain tumors, CSF has been implicated in tumor pathogenesis by serving as both a reservoir and vehicle for factors which may support tumor progression, therefore contributing to the tumor microenvironment. Pathological manifestations of CSF in the setting of brain tumors include hydrocephalus due to tumor obstruction of CSF pathways, CSF seeding and leptomeningeal metastasis, and transependymal flow. CSF also has roles as a reservoir for biomarkers important in brain tumor detection and as a site for direct delivery of therapeutic agents to bypass the blood brain barrier. Despite the intimate association between CSF and brain tumors, few studies have investigated mechanisms of local and global alterations of fluid flow in the setting of glioma, the most common malignant primary brain tumor in the central nervous system. Here, we provide an overview of recent advances in our understanding of the roles, implications, regulations, and diagnostic/therapeutic implications of CSF in glioma and how they may be leveraged for research and clinical application.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"166 ","pages":"33-57"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid biopsy in the diagnosis of primary brain tumors. 液体活检在原发性脑肿瘤诊断中的应用。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-06 DOI: 10.1016/bs.acr.2025.05.004

Tejus A Bale, Ingo K Mellinghoff, Maya S Graham

引用次数: 0

Molecularly driven therapies in the treatment of primary brain tumors. 分子驱动疗法在原发性脑肿瘤治疗中的应用。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-27 DOI: 10.1016/bs.acr.2025.05.005

Ruham Alshiehk Nasany, Macarena I de la Fuente

{"title":"Molecularly driven therapies in the treatment of primary brain tumors.","authors":"Ruham Alshiehk Nasany, Macarena I de la Fuente","doi":"10.1016/bs.acr.2025.05.005","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.05.005","url":null,"abstract":"Molecular profiling has revolutionized the diagnosis, classification, and treatment of various cancers, with advances in next-generation sequencing and DNA methylation profiling offering unprecedented insights into tumor biology. This paradigm shift has enhanced the understanding of driver mutations in cancers translating into improved patient outcomes. In primary brain tumors, particularly gliomas, molecular profiling has redefined classification frameworks, yet meaningful improvements in patient survival remain elusive, particularly for glioblastoma. However, recent strides in molecularly targeted therapies have led to landmark FDA approvals, including agents such as vorasidenib for IDH-mutant gliomas, the combination of dabrafenib trametinib for BRAF mutated tumors, and TRK inhibitors for NTRK fusion-positive tumors. While conventional treatments like surgery, radiation, and chemotherapy remain the standard of care for gliomas, the integration of molecular-driven therapies is beginning to shape clinical management strategies. This article explores the evolving role of molecularly targeted treatments in adult primary brain tumors, examining their current applications and future potential.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"166 ","pages":"183-201"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid biopsy in early detection and monitoring of CNS metastases. 液体活检在早期发现和监测中枢神经系统转移中的作用。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-21 DOI: 10.1016/bs.acr.2025.04.007

Natasha Hongsermeier-Graves, Mohammed Hasen, Noah Yaffe, Andrew Ajisebutu, Rachna Malani

引用次数: 0

Preface. 前言。

Advances in cancer research Pub Date : 2025-01-01 DOI: 10.1016/S0065-230X(25)00042-9

Mariza Daras, David D Limbrick, Paul B Fisher

引用次数: 0

Molecular drivers in CNS metastatic disease. 中枢神经系统转移性疾病的分子驱动因素。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-30 DOI: 10.1016/bs.acr.2025.04.004

Hannah Kim, Sofia Chernet, Priya Kumthekar, Akanksha Sharma

引用次数: 0

Molecular drivers in primary brain tumor formation. 原发性脑肿瘤形成的分子驱动因素。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-25 DOI: 10.1016/bs.acr.2025.04.006

Hope T Richard

引用次数: 0

Advanced imaging of IDH-mutant gliomas: Precision in diagnosis and management. idh突变胶质瘤的先进影像学：诊断和治疗的准确性。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-18 DOI: 10.1016/bs.acr.2025.05.003

Onur Yildirim, Robert J Young

{"title":"Advanced imaging of IDH-mutant gliomas: Precision in diagnosis and management.","authors":"Onur Yildirim, Robert J Young","doi":"10.1016/bs.acr.2025.05.003","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.05.003","url":null,"abstract":"Advancements in imaging techniques and analyses have evolved in parallel with advancements in precision oncology and the transformative changes in glioma diagnosis and management. This chapter explores the pivotal roles of modern qualitative and quantitative imaging in characterizing gliomas, particularly low-grade gliomas (LGGs). Key topics include the integration of standard imaging biomarkers (e.g., T2-FLAIR mismatch sign) and advanced imaging modalities (e.g., 2-hydroxyglutarate [2HG] spectroscopy, diffusion and perfusion imaging) into routine clinical practice. These approaches enhance diagnostic accuracy, facilitate treatment planning, and enable longitudinal monitoring of disease progression. Practical challenges, such as the logistical demands to implement tumor segmentation, variability in imaging acquisition and interpretation, and integration of imaging into decision-making discussions between physicians and patients, are also discussed. Additionally, the role of radiomics and artificial intelligence (AI) in refining tumor characterization and predicting treatment response is explored. The inclusion of emerging therapeutic strategies, including IDH inhibitors and AI-driven imaging tools, underscores this chapter's emphasis on precision-driven innovations. By synthesizing current research and clinical practices, this chapter provides a comprehensive framework for leveraging advanced imaging in glioma care. Improved imaging methodologies not only allow for earlier detection of disease progression but also offer insight into treatment response and resistance mechanisms. As imaging continues to evolve, its integration with molecular and computational tools will further refine personalized approaches in glioma management, ultimately contributing to better patient outcomes.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"166 ","pages":"59-80"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supramaximal resection in primary brain tumors. 原发性脑肿瘤的上极切除。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-18 DOI: 10.1016/bs.acr.2025.05.006

Vardhaan S Ambati, Shawn L Hervey-Jumper

引用次数: 0

Advances in minimally invasive surgery for brain metastases. 微创手术治疗脑转移瘤的进展。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-08 DOI: 10.1016/bs.acr.2025.04.003

Nicole A Perez, Bryan D Choi, Brian V Nahed

{"title":"Advances in minimally invasive surgery for brain metastases.","authors":"Nicole A Perez, Bryan D Choi, Brian V Nahed","doi":"10.1016/bs.acr.2025.04.003","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.04.003","url":null,"abstract":"Brain metastases (BMs) affect approximately 10-30 % of cancer patients, and their prevalence is growing as patients live longer with controlled primary disease. Surgical resection remains a cornerstone of treatment for both solitary and multifocal lesions. Since the advent of intracranial tumor surgery, neurosurgery has trended towards less invasive surgical approaches, facilitated by a proliferation of surgical innovations ranging from intraoperative MRI to tubular retractors. Minimally invasive cranial surgery (MICS) incorporates approaches such as keyhole craniotomies and tubular retraction with the goal of maximizing extent of resection and reducing iatrogenic tissue injury. Supramarginal resection builds upon this approach, expanding the boundaries of the resection cavity to ensure removal of microscopic tumor fragments and decrease recurrence. Because MICS is generally performed through craniotomies< 5 cm in diameter with limited ability to change predefined surgical corridors intraoperatively, meticulous attention must be given to the preoperative workup. Imaging modalities, including CT, MRI, DWI, and DTI, may reveal characteristics of the intra-tumoral environment and are important in defining the anatomical relationship of BMs to surrounding functional tissue and neurovascular structures. Intraoperatively, neuronavigation helps maintain alignment within predefined surgical corridors, and adjunctive modalities such as intraoperative ultrasound and brain mapping help compensate for brain shift. Advancements in visual augmentation tools such as fluorescence, endoscopes, and exoscopes further enable intraoperative delineation of tumor boundaries and allow for expanded utilization of MICS in deep-seated, complex BMs. The ever-growing armamentarium of minimally invasive surgical tools has made neurosurgery an increasingly safe and effective option for patients with BMs.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"165-230"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0